9 completed, 4 recruiting, 4 terminated, 1 active not recruiting. 5 Not applicable, 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
Follow Thrombasthenia: new trials by email Literature Review of Thrombasthenia trials Research Report on Thrombasthenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531) EPTACOG BETA - Glanzmann Thrombasthenia | Phase 2 | Recruiting | Emory University | 6 | 2025-10-02 | 2025-12-01 |
| ATHNdataset Registry Hemophilia, Thrombosis | Recruiting | American Thrombosis and Hemostasis Network | 200000 | 2024-10-25 | 2026-04-21 | |
| Multinational Glanzmann Study Glanzmann Thrombasthenia | Not yet recruiting | UMC Utrecht | 200 | 2024-03-01 | 2024-02-28 | |
| Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases Sublingual videomicroscopy, blood sample - Von Willebrand Diseases, Glanzmann Thrombasthenia | Not applicable | Recruiting | University Hospital, Lille | 400 | 2023-05-24 | 2026-05-20 |
| Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen, : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM, Thrombin Generation Assay (TGA) in PRP using TF trigger - Glanzmann Thrombasthenia | Not applicable | Completed | University Hospital, Bordeaux | 20 | 2023-04-06 | 2026-05-26 |
| A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia HMB-001 - Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Active not recruiting | Hemab ApS | 57 | 2022-12-13 | 2026-09-25 |
| The Experiences of People Who Live With Glanzmanns Thrombasthenia. survey and interview - Glanzmann Thrombasthenia | Completed | Haemnet | 122 | 2022-04-27 | 2024-03-13 | |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) Antibodies screening - Glanzmann Thrombasthenia | Not applicable | Completed | University Hospital, Bordeaux | 28 | 2021-01-06 | 2026-05-22 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Completed | AryoGen Pharmed Co. | 200 | 2016-06-13 | 2022-02-15 | |
| A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan eptacog alfa (activated) - Congenital Bleeding Disorder, Glanzmann's Disease | Completed | Novo Nordisk A/S | 4 | 2014-10-07 | 2017-07-11 | |
| Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen - Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 38 | 2014-09-02 | 2025-03-03 |
| Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Abatacept - Hurler Syndrome, Fanconi Anemia | Phase 1 | Completed | Emory University | 10 | 2014-01-01 | 2019-12-26 |
| Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Alefacept - Thalassemia, Sickle Cell Disease | Not applicable | Terminated | Emory University | 3 | 2010-09-01 | 2017-07-27 |
| Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany eptacog alfa (activated) - Congenital Bleeding Disorder, Congenital FVII Deficiency | Completed | Novo Nordisk A/S | 64 | 2008-06-01 | 2016-12-07 | |
| Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects activated recombinant human factor VII - Acquired Bleeding Disorder, Acquired Haemophilia | Phase 1 | Completed | Novo Nordisk A/S | 28 | 2006-04-01 | 2017-01-19 |
| The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders. Glanzmann Thrombasthenia | Recruiting | Rockefeller University | 60 | 2005-09-01 | 2025-10-20 | |
| Observational Registry of the Treatment of Glanzmann's Thrombasthenia activated recombinant human factor VII - Congenital Bleeding Disorder, Glanzmann's Disease | Completed | Novo Nordisk A/S | 218 | 2004-01-01 | 2014-12-23 |
Anemia, Sickle Cell (5) · Anemia, Diamond-Blackfan (4) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (4) · Shwachman-Diamond Syndrome (4) · Anemia, Aplastic (3) · Granulomatous Disease, Chronic (3) · Wiskott-Aldrich Syndrome (3) · Chediak-Higashi Syndrome (2) · Dyskeratosis Congenita (2) · Factor VII Deficiency (2) · Fanconi Anemia (2) · Hemoglobinuria, Paroxysmal (2) · Hemorrhage (2) · Leukocyte adhesion deficiency type 1 (2)
Blood Coagulation Disorders (19) · Blood Coagulation Disorders, Inherited (19) · Blood Platelet Disorders (19) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19) · Genetic Diseases, Inborn (19) · Hemic and Lymphatic Diseases (19) · Hemorrhagic Disorders (19) · Hematologic Diseases (18) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Anemia (5) · Anemia, Hemolytic (5) · Anemia, Hemolytic, Congenital (5) · Hemoglobinopathies (5) · Anemia, Hypoplastic, Congenital (4)
recombinant FVIIa (3) · Factor VII (2) · Abatacept (1) · Alefacept (1) · Blood Specimen Collection (1) · Collagen (1) · Cyclophosphamide (1) · Interviews as Topic (1) · Peripheral Blood Stem Cell Transplantation (1) · Surveys and Questionnaires (1) · Thromboplastin (1) · Whole-Body Irradiation (1) · concizumab (1) · fludarabine phosphate (1)
Novo Nordisk A/S (4) · Emory University (3) · University Hospital, Bordeaux (2) · American Thrombosis and Hemostasis Network (1) · AryoGen Pharmed Co. (1) · Catalyst Biosciences (1) · Haemnet (1) · Hemab ApS (1) · Masonic Cancer Center, University of Minnesota (1) · Rockefeller University (1) · Roswell Park Cancer Institute (1) · UMC Utrecht (1) · University Hospital, Lille (1)
United States (10) · France (6) · Italy (3) · United Kingdom (3) · Belgium (2) · Germany (2) · Netherlands (2) · Algeria (1) · Austria (1) · Bulgaria (1) · Hungary (1) · India (1) · Iran (1) · Japan (1) · Pakistan (1)
Antoine Rauch, MD,PhD (1) · Ashish Gupta, MBBS, MPH (1) · Barry Coller, MD (1) · John Horan, MD (1) · John T Horan, MD (1) · Karen Zimowski, MD (1) · Mike Holland, BSC (1) · Mohammad Faranoush, MD (1) · Philip McCarthy, MD (1) · Tammuella Chrisentery-Singleton, M.D. (1)
PMID 17880439, PMID 26001792, PMID 26001793, PMID 26095669, PMID 31523745, PMID 36924249, PMID 38880178
2005 (1), R01HL019278 (1)